ATTR-CM study results hATTR-PN study results

Proven to help people with ATTR-CM live longer

Select a group in the study to see results for people not taking a stabilizer at the start of the study.

The combined risk of death and heart-related hospital visits was lower over 3 years with AMVUTTRA® (vutrisiran).*

Fewer people taking AMVUTTRA had at least one heart-related hospital visit or death over 3 years.*

*

Most deaths were heart‑related. Hospital visits included hospital stays and urgent visits.

Build your personalized discussion guide

This Doctor Discussion Guide can help you prepare for your next appointment and discuss your treatment goals.

If you're the caregiver of someone with ATTR-CM, complete this guide together.

Or, you can download a version to print and fill out.

By submitting this form, I agree to the Alnylam Privacy Policy and the Consumer Health Data Privacy Policy, including the collection of my health-related personal information. I am 18 years or older, a US resident, and consent to the processing of my personal data per the terms outlined in the Data Privacy Notification and Consent, by Alnylam and Alnylam’s partners. I understand that Alnylam will use reasonable technical and organizational measures to protect the information I share when completing this personalized discussion guide.

Up Next

How AMVUTTRA May Help hATTR-PN

Important Safety Information

What are the most important things I should know about AMVUTTRA® (vutrisiran)?

AMVUTTRA can cause low vitamin A levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the:

cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce heart-related death, hospital stays and urgent visits.
polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

Important Safety Information and Indications

Important Safety Information

What are the most important things I should know about AMVUTTRA® (vutrisiran)?

AMVUTTRA can cause low vitamin A levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the:

cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce heart-related death, hospital stays and urgent visits.
polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

Proven to help people with ATTR-CM live longer

How AMVUTTRA May Help hATTR-PN

Important Safety Information

Indications

Important Safety Information

Indications

The site you are about to enter is intended for US healthcare professionals.

You are now leaving amvuttra.com

You are now leaving amvuttra.com

This email address is already in use.

Email sent!

SIGN UP FOR EDUCATIONAL EMAILS

REQUEST TO CONNECT WITH AN ALNYLAM EDUCATOR